BTK and myeloid sarcoma: The positive effect of evobrutinib on MS was explained by its impact on B-cells and myeloid cells, which play a key role in the pathophysiology of MS, and by its crossing of the blood–brain barrier apparently achieving a high Btk occupancy in the CNS.